Clinical Trial Update: Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 trial of U3-1287 in combination with trastuzumab and paclitaxel for newly diagnosed metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)
• U3-1287

Snippet

Sponsor: Daiichi Sankyo | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED